Archer successfully produces batteries with Campoona graphite


Published 21-AUG-2018 14:47 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Archer Exploration (ASX:AXE) has provided an update on its collaboration with the University of New South Wales (UNSW).

Functional full-cell lithium ion batteries, which utilise the company’s Campoona graphite have been successfully assembled. In addition, the batteries are commercially scalable and have been validated for performance.

AXE’s Campoona graphite was utilised at the anode, while commercially equivalent cathode materials and chemistries used in consumer electronics and electric vehicles.

Yet it remains a speculative stock and investors and investors should take a cautious approach to any investment decision made with regard to this stock.

Lithium-nickel-manganese-cobalt (NMC), lithium-iron phosphate (LFP) and lithium-cobalt oxide (LCO) were used to construct the full-cells – with the batteries being prepared as coin-cells (resembling a coin).

AXE coin-cell batteries

AXE’s 99% acid-leached graphite from Campoona was used without further optimisation. The NMC and LCO cathode bodies were prepared at UNSW, with the LFP cathode commercially sourced.

Synthesis, fabrication, characterisation and testing was undertaking by the UNSW on campus. Key performance standards were in line with industry state-of-art values, due in part to the exceptional properties of the company’s Campoona graphite.

AXE CEO Dr Mohammad Choucair commented on the promising development, “The speed in which we are able to deliver such exceptional outcomes is testament to the strong technical leadership and culture of excellence at Archer.

“Collaboration with UNSW has greatly accelerated our advance in the battery space. We are now able to demonstrate complete, functioning, and commercially relevant batteries with Archer’s graphite.

“We have reached a major milestone towards integrating our substantial graphite resource in the lithium ion battery supply chain. The work definitively shows that Archer’s graphite can be used in conjunction with different types of cathodes, making it suitable for multiple potential battery markets.”

Next steps

AXE will now turns its focus to addressing the trade-off between cost and battery performance. The company will continue to seek partnerships with lithium ion battery manufacturers to scale and integrate Campoona graphite further in the supply chain.

The ongoing collaboration with UNSW will continue, with the intention of generating add on value to AXE’s proposed Campoona development through the co-development of IP geared around ultra-high graphite purity.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free